Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

项目摘要/摘要-临床核心(CC) 临床核心(CC)将提供和协调现有生物信息库和新的预期临床的共享 从全身和粘膜(肠道和鼻咽)隔室收集的样本来自过去和 正在进行的儿童早期队列，以能够表征疫苗反应特异性的呼吸道感染- 特定的和哮喘特定的基因组特征和内型。这些发现将为干预措施提供信息 可能会将与疾病相关的不利理想内型重新定向到与健康相关的那些。具体来说， 消委会将： 1.协调从四个早期生命队列(EPIC-HIPC、VDAART、 Rochester联合队列(RCC)和CHILD)，这将共同构成我们理想的Meta队列(IMC)以 基因组和免疫分析的核心/项目； 2.测量VDART和儿童队列中疫苗诱导的抗体水平；以及 3.招募一个定义明确的潜在婴儿队列，为验证测试提供新的样本，确认 预测生物标记物、检验机械假说、识别免疫调节剂(例如，蛋白质， 代谢物、佐剂或疫苗)克服受损的表型，并为未来确保新的生物储存库 调查。

Project Summary/Abstract – Clinical Core (CC) The Clinical Core (CC) will provide and coordinate sharing of existing biorepository and new prospective clinical samples collected from the systemic and mucosal (intestinal and nasopharyngeal) compartments from past and ongoing early childhood cohorts to enable characterization of vaccine response-specific, respiratory infection- specific, and asthma-specific OMIC signatures and endotypes. These discoveries will inform interventions that may redirect unfavorable IDEAL endotypes associated with disease to those associated with health. Specifically, the CC will: 1. Coordinate transfer of biorepository clinical samples from the four early life cohorts (EPIC-HIPC, VDAART, Rochester Combined Cohort (RCC), and CHILD) that together will comprise our IDEAL Meta Cohort (IMC) to Cores/Projects for OMIC and immune assays; 2. Measure vaccine induced antibody levels in VDART and CHILD cohorts; and 3. Recruit a well-defined prospective infant cohort to provide new samples for validation testing, confirm predictive biomarkers, test mechanistic hypotheses, identify immunomodulatory agents (e.g., proteins, metabolites, adjuvants or vaccines) overcoming impaired phenotype, and secure a new biorepository for future investigations.